(REGN) Regeneron Pharmaceuticals - Overview
Stock: Injection, Ophthalmology, Dermatology, Oncology, Immunology
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.54% |
| Yield on Cost 5y | 0.91% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | 8.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 35.7% |
| Relative Tail Risk | -5.51% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.33 |
| Alpha | -0.41 |
| Character TTM | |
|---|---|
| Beta | 0.564 |
| Beta Downside | 0.334 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.69% |
| CAGR/Max DD | 0.02 |
Description: REGN Regeneron Pharmaceuticals January 29, 2026
Regeneron Pharmaceuticals (NASDAQ: REGN) discovers, invents, develops, manufactures, and commercializes a diversified portfolio of biologic medicines, including EYLEA for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for cutaneous squamous cell carcinoma, and REGEN-COV for COVID-19, among others.
In its most recent fiscal year (2023), Regeneron reported $13.2 billion in total revenue, a 6 % year-over-year increase driven primarily by growth in EYLEA and Dupixent sales; Q3 2024 revenue was $3.4 billion, with an adjusted EPS of $6.02 and R&D spending representing 20 % of revenue, underscoring continued investment in pipeline candidates.
The pipeline includes late-stage programs such as an in-vivo CRISPR gene-editing therapy with Mammoth Biosciences, engineered regulatory T-cell therapies with Sonoma Biotherapeutics, and TSRA-196 for Alpha-1 antitrypsin deficiency with Tessera Therapeutics, all targeting high-unmet-need indications across ophthalmology, immunology, oncology, and rare diseases.
Key sector drivers that affect Regeneron’s outlook are the projected 9 % CAGR in global biologics sales through 2028, aging demographics increasing demand for chronic-disease therapies, and expanding reimbursement frameworks for gene-editing and cell-based treatments.
For a deeper quantitative analysis, see the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 4.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.53 > 1.0 |
| NWC/Revenue: 153.2% < 20% (prev 103.6%; Δ 49.58% < -1%) |
| CFO/TA 0.12 > 3% & CFO 4.98b > Net Income 4.50b |
| Net Debt (-16.16b) to EBITDA (5.82b): -2.78 < 3 |
| Current Ratio: 4.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.5m) vs 12m ago -5.54% < -2% |
| Gross Margin: 85.35% > 18% (prev 0.86%; Δ 8449 % > 0.5%) |
| Asset Turnover: 36.63% > 50% (prev 37.61%; Δ -0.98% > 0%) |
| Interest Coverage Ratio: 120.4 > 6 (EBITDA TTM 5.82b / Interest Expense TTM 43.8m) |
Altman Z'' 10.00
| A: 0.54 (Total Current Assets 27.81b - Total Current Liabilities 5.83b) / Total Assets 40.56b |
| B: 0.88 (Retained Earnings 35.80b / Total Assets 40.56b) |
| C: 0.13 (EBIT TTM 5.27b / Avg Total Assets 39.16b) |
| D: 3.86 (Book Value of Equity 35.87b / Total Liabilities 9.30b) |
| Altman-Z'' Score: 11.39 = AAA |
Beneish M -3.40
| DSRI: 0.92 (Receivables 5.74b/6.21b, Revenue 14.34b/14.20b) |
| GMI: 1.01 (GM 85.35% / 86.13%) |
| AQI: 0.49 (AQ_t 0.19 / AQ_t-1 0.38) |
| SGI: 1.01 (Revenue 14.34b / 14.20b) |
| TATA: -0.01 (NI 4.50b - CFO 4.98b) / TA 40.56b) |
| Beneish M-Score: -3.40 (Cap -4..+1) = AA |
What is the price of REGN shares?
Over the past week, the price has changed by +5.94%, over one month by +1.16%, over three months by +21.58% and over the past year by +9.39%.
Is REGN a buy, sell or hold?
- StrongBuy: 14
- Buy: 5
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the REGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 859.6 | 9.4% |
| Analysts Target Price | 859.6 | 9.4% |
| ValueRay Target Price | 798.9 | 1.7% |
REGN Fundamental Data Overview February 07, 2026
P/E Forward = 17.6056
P/S = 5.6507
P/B = 2.6061
P/EG = 1.4741
Revenue TTM = 14.34b USD
EBIT TTM = 5.27b USD
EBITDA TTM = 5.82b USD
Long Term Debt = 1.99b USD (from longTermDebt, two quarters ago)
Short Term Debt = 37.8m USD (from shortTermDebt, last quarter)
Debt = 2.71b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -16.16b USD (from netDebt column, last quarter)
Enterprise Value = 75.15b USD (81.05b + Debt 2.71b - CCE 8.61b)
Interest Coverage Ratio = 120.4 (Ebit TTM 5.27b / Interest Expense TTM 43.8m)
EV/FCF = 18.42x (Enterprise Value 75.15b / FCF TTM 4.08b)
FCF Yield = 5.43% (FCF TTM 4.08b / Enterprise Value 75.15b)
FCF Margin = 28.45% (FCF TTM 4.08b / Revenue TTM 14.34b)
Net Margin = 31.41% (Net Income TTM 4.50b / Revenue TTM 14.34b)
Gross Margin = 85.35% ((Revenue TTM 14.34b - Cost of Revenue TTM 2.10b) / Revenue TTM)
Gross Margin QoQ = 84.95% (prev 86.11%)
Tobins Q-Ratio = 1.85 (Enterprise Value 75.15b / Total Assets 40.56b)
Interest Expense / Debt = 0.45% (Interest Expense 12.2m / Debt 2.71b)
Taxrate = 19.08% (199.1m / 1.04b)
NOPAT = 4.27b (EBIT 5.27b * (1 - 19.08%))
Current Ratio = 4.77 (Total Current Assets 27.81b / Total Current Liabilities 5.83b)
Debt / Equity = 0.09 (Debt 2.71b / totalStockholderEquity, last quarter 31.26b)
Debt / EBITDA = -2.78 (Net Debt -16.16b / EBITDA 5.82b)
Debt / FCF = -3.96 (Net Debt -16.16b / FCF TTM 4.08b)
Total Stockholder Equity = 30.39b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.50% (Net Income 4.50b / Total Assets 40.56b)
RoE = 14.83% (Net Income TTM 4.50b / Total Stockholder Equity 30.39b)
RoCE = 16.29% (EBIT 5.27b / Capital Employed (Equity 30.39b + L.T.Debt 1.99b))
RoIC = 13.31% (NOPAT 4.27b / Invested Capital 32.08b)
WACC = 7.74% (E(81.05b)/V(83.75b) * Re(7.99%) + D(2.71b)/V(83.75b) * Rd(0.45%) * (1-Tc(0.19)))
Discount Rate = 7.99% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -2.81%
[DCF Debug] Terminal Value 77.58% ; FCFF base≈3.89b ; Y1≈3.53b ; Y5≈3.07b
Fair Price DCF = 713.3 (EV 57.95b - Net Debt -16.16b = Equity 74.11b / Shares 103.9m; r=7.74% [WACC]; 5y FCF grow -11.54% → 2.90% )
EPS Correlation: 30.97 | EPS CAGR: 6.83% | SUE: 0.43 | # QB: 0
Revenue Correlation: 77.36 | Revenue CAGR: 7.47% | SUE: 0.52 | # QB: 0
EPS next Quarter (2026-03-31): EPS=9.15 | Chg30d=-1.329 | Revisions Net=+2 | Analysts=20
EPS current Year (2026-12-31): EPS=44.56 | Chg30d=+0.236 | Revisions Net=+5 | Growth EPS=+0.6% | Growth Revenue=+8.8%
EPS next Year (2027-12-31): EPS=46.83 | Chg30d=-0.412 | Revisions Net=+1 | Growth EPS=+18.6% | Growth Revenue=+9.6%